Small cap bio-tech based in Perth, Australia. Entering deals with Glaxosmithkline (GSK) and other TNC pharmas. Currently at year lows SP wise, when the deal with GSK is finalized concerning OBJ's FIM technology (currently in human testing) the SP will see a rerating up to possibly 20 cents (10 fold).
We should see an announcement regarding progress with GSK within the next 3 months, this announcement will stipulate milestone payments and a commercialization framework for OBJ's FIM technology.
It is just a matter of time with OBJ, prices are low, might as well accumulate.
No comments:
Post a Comment